With over 400,000 new cases every year, Lyme disease is one of the most significant and fastest growing infectious diseases in the US, yet Lyme disease research remains significantly underfunded relative to other illnesses of this magnitude. There are too many unanswered questions about the Borrelia burgdorferi bacteria, its transmission, and its impact on human health.  The time to make a difference is now.

More Answers Are Needed

Tick populations and tick-borne infections like Lyme disease appear to be on the rise, potentially due to climate change, though there is no research definitively proving cause or suggesting solutions.

Newer bacterial strains and species, like Borrelia miyamotoi which has Lyme-like symptoms, have only recently been discovered and present equally severe risks to public health.

Lyme symptoms are highly variable and current laboratory diagnostics are notoriously unreliable at detecting the elusive bacteria.

Current treatment regimens for late stage Lyme are inconsistent and sustained antibiotic courses can undermine patient health.

Prevent › Diagnose › Treat

As an independent nonprofit organization, Bay Area Lyme is able to partner with leading researchers and institutions all across the country to support the most innovative and promising projects in Lyme disease research, regardless of affiliation.

True breakthroughs will occur only through well-designed research projects and at Bay Area Lyme, we have a rigorous screening and monitoring process, grant contingencies, and project reporting, to ensure that projects are effectively designed and funds well spent.

With a clear objective to develop more effective means of diagnosing, treating, and preventing this disease, our Lyme disease research has three primary areas of focus:

  • Lyme and tick ecology –  understanding the basic pathogenesis of Lyme disease and related tick-borne-bacteria, their transmission through ticks and other intermediate hosts, and the impact of local ecological conditions on their prevalence and virulence
  • Diagnostics– leveraging new technologies and methodologies to improve both acute and late stage diagnosis through direct and indirect tests for DNA, RNA, antigens, antibodies, cytokines, metabolites, or other biomarkers
  • Treatment efficacy and alternatives – examining new and alternative approaches and adjunctive therapies to help the body fight infection (in conjunction with antibiotics and for weakened and non-functioning immune systems)

Main photo courtesy of Graham Hickling